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The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) is associated with Kaposi’s sarcoma (KS) as
well as primary effusion lymphomas (PEL). The expression of viral proteins capable of inactivating the p53
tumor suppressor protein has been implicated in KSHV oncogenesis. However, DNA-damaging drugs such as
doxorubicin are clinically efficacious against PEL and KS, suggesting that p53 signaling remains intact despite
the presence of KSHV. To investigate the functionality of p53 in PEL, we examined the response of a large
number of PEL cell lines to doxorubicin. Two out of seven (29%) PEL cell lines harbored a mutant p53 allele
(BCBL-1 and BCP-1) which led to doxorubicin resistance. In contrast, all other PEL containing wild-type p53
showed DNA damage-induced cell cycle arrest, p53 phosphorylation, and p53 target gene activation. These data
imply that p53-mediated DNA damage signaling was intact. Supporting this finding, chemical inhibition of p53
signaling in PEL led to doxorubicin resistance, and chemical activation of p53 by the Hdm2 antagonist Nutlin-3
led to unimpaired induction of p53 target genes as well as growth inhibition and apoptosis.
Primary effusion lymphoma (PEL) or body cavity-based lym-
phoma is a rapidly progressive disease often arising in the
context of human immunodeficiency virus (HIV)/AIDS, but it
is also seen in HIV-negative transplant recipients and in the
elderly. PEL exists as a fluid tumor of B-cell origin within the
serous cavities of the body. Current multidrug chemotherapies
against PEL, such as CHOP (cyclophosphamide, doxorubicin
[Dox], vincristine, and prednisone) target proliferating cells
and typically include a DNA-damaging agent such as doxoru-
bicin. These therapies are initially successful (64). However,
the immunocompromised status of PEL patients makes them
highly susceptible to the myelosuppressive side effects of high-
dose chemotherapy regimens. As a result, the median survival
time for those diagnosed with PEL is typically less than 3
months (1, 12), and there exists an urgent need for novel
therapies against PEL.
All PEL tumor cells are infected with Kaposi’s sarcoma-
associated herpesvirus (KSHV) (13, 49). KSHV is a member of
the gamma-herpesviruses and was first isolated in the AIDS-
associated malignancy Kaposi’s sarcoma (KS) (15). KSHV re-
mains largely latent in PEL and expresses only a limited set of
genes, including Kaposin/K12, v-cyclin/orf72, the latency-asso-
ciated nuclear antigen (LANA)/ORF73, v-FLIP/ORF71, and
the viral micro-RNAs (19, 26) (8, 23, 35, 51, 53, 58, 59). PEL
are dependent upon KSHV for survival, as loss of the KSHV
genome results in cell death (30). These results suggest that
one or more KSHV oncogenes are essential for PEL survival.
Following the precedence of the small DNA tumor viruses
such as simian virus 40 and human papilloma virus, KSHV too
was hypothesized to contain viral genes that curb p53 function
and thereby mediate viral oncogenesis.
p53 has been deemed the most frequently mutated gene in
human cancer, with the majority of alterations localizing to the
protein’s DNA binding domain (reviewed in reference 32). In
response to DNA-damaging chemotherapeutics, p53 is acti-
vated and functions as a sequence-specific transcription factor
for a well-defined set of p53-responsive promoters. This in turn
leads to a variety of cellular outcomes, including cell cycle
arrest and apoptosis (reviewed in reference 69). p53 stability is
tightly regulated by the ubiquitin ligase activity of the human
Mdm2 homologue, Hdm2 (reviewed in reference 34). Overex-
pression of Hdm2 is frequently noted in human cancers and
provides a mechanism to inactivate p53 epigenetically (45).
The Mdm2-p53 binding site is well defined (44), and recently
novel compounds, such as Nutlin-3, that inhibit the Hdm2-p53
interaction have been proposed as therapeutics for tumors
maintaining wild-type p53 status (33, 68). Nutlin-3, unlike
doxorubicin, does not induce cellular DNA damage, thus al-
lowing for the direct assessment of p53 function independent
of any other effects that may be induced by DNA-damaging
drugs. Neither the efficacy of Nutlin-3 for PEL treatment nor
the functional status of p53 in the context of KSHV-positive
tumor cells has been previously studied.
To examine p53 functionally in KSHV-associated cancers,
we employed the largest set of patient-derived PEL lines pub-
lished to date. As previously reported for clinical PEL and KS
biopsies (14, 38, 46), we found that p53 mutations were infre-
quent in PEL even after continued passage in culture (two of
seven lines). The wild-type p53 genotype translated into a
wild-type p53 phenotype, as PEL cells responded to physiolog-
ically relevant levels of doxorubicin. PEL treatment with doxo-
rubicin led to p53 phosphorylation, activation of downstream
target genes, and subsequent cell cycle arrest, consistent with
an intact p53 signaling pathway. Moreover, PEL lines re-
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sponded to Nutlin-3 in a p53- and Hdm2-dependent manner,
evidencing a functional p53-Hdm2 pathway.
MATERIALS AND METHODS
Cell culture and materials. PEL cells and cell culture conditions were previ-
ously described (Table 1) (2, 5, 7, 10, 13, 29, 42). Doxorubicin and Nutlin-3
(racemic) were obtained from Sigma and diluted in dimethyl sulfoxide (DMSO).
Pifithrin- was obtained from Alexis Biochemicals and stored in DMSO.
p53 sequencing. cDNA was prepared from all PEL cell lines using the RNeasy
mini kit (QIAGEN), 100 U of Superscript II reverse transcriptase (Life Tech-
nologies), and random hexanucleotide primers (Amersham Pharmacia Biotech).
The resulting cDNA was used to PCR amplify two regions of the p53 DNA
binding domain spanning amino acids (aa) 126 to 224 and aa 225 to 331. The
primers were as follows: aa 126 to 224 forward, 5-TCTCCTTCCTCTTCCTAC
AG-3; reverse, 5-ACCCCAGTTGCAAACCAGAC-3; aa 225 to 331 forward,
5-GGGCCTGTGTTATCTCCTAG-3; reverse, 5-GAGGTCCCAAGACTTA
GTAC-3. PCR was performed using the GeneAmp High Fidelity PCR system
(Applied Biosystems) according to the manufacturer’s instructions. The resulting
PCR products were cloned into pBluescript II KS() (Stratagene) and se-
quenced.
MTT/cell viability assays. On day 0, cells were seeded at 3  105 cells/1.5 ml
complete media in 12-well dishes, and drugs and/or was vehicle added. Each day
thereafter, 50 l of cells was removed and incubated in a 96-well plate with 0.1
mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide;
Sigma) for 4 h at 37°C and 5% CO2. The reaction was stopped, and formazan
crystals were dissolved in a 0.1 N HCl-isopropanol solution. MTT metabolism
(at an optical density of 570 nm [OD570]) was read and normalized to cell density
(OD690). All assays were performed in triplicate. Graphs display the average
growth relative to the untreated sample at day 1. Error bars represent the
standard deviation. Alternatively, cell viability was determined from the 50-l
samples via trypan blue exclusion. The 50% inhibitory concentration (IC50) was
calculated using a sigmoidal dose-response fit of the MTT assay results on day 4
and GraphPad Prism 4 software (GraphPad Software).
Western blotting. Cells were seeded in two flasks each containing 40 ml
complete media at a concentration of 2  105 cells/ml. The following morning,
0.025 g/ml doxorubicin was added to both flasks, and 20 ml of one culture was
immediately harvested (t  0 h). Eight, 24, and 48 h postdrug addition, 20 ml of
culture was removed and centrifuged, and the cell pellet stored at 80°C. The
resulting pellets were lysed in radioimmunoprecipitation assay buffer (150 mM
NaCl, 1.0% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], and
50 nM Tris [pH 8.0]) containing 1 nM phenylmethylsulfonyl fluoride, 1 pro-
tease inhibitor cocktail (Sigma), 10 nM sodium fluoride, 1 mM sodium vanadate,
and 60 mM -glycerophosphate. Lysates were quantified using the BCA Protein
Assay kit (Pierce Inc.), and proteins were separated on SDS–12% polyacryl-
amide gels. Gels were transferred to Hybond-P (Amersham Biosciences) and
probed for the indicated protein products. Primary antisera utilized were the
following: p53 phosophoserine 15 (1:1,000; Cell Signaling), total p53 (1:1,000;
Santa Cruz Biotechnologies), p21 (1:500; Santa Cruz), CDK6 (1:1,000; Santa
Cruz), and Hdm2 (1:500; Ab-1; Calbiochem). Following incubation with horse-
radish peroxidase-conjugated secondary antibodies (goat--mouse immunoglob-
ulin G; Santa Cruz; and goat--rabbit immunoglobulin G; Vector Laboratories
Inc.) and ECL substrate (Pierce Inc.), antibody-antigen complexes were visual-
ized via autoradiography. Quantification of protein expression was conducted
using ImageQuant software. Hdm2 levels were normalized to CDK6 (loading
control). The relative level of p21 was determined using ImageJ software (Wayne
Rashband, National Institutes of Health). Specifically, p21 band density was first
normalized to CDK6 (loading control) and then the quantity was determined
relative to 0 h for each cell line.
Flow cytometry. Cells were seeded and treated as described for the Western
blotting experiments. At 0, 8, 24, and 48 h postdrug addition, cells were har-
vested by centrifugation, fixed, and stained as we previously described (20,
52). Cells were analyzed on a Becton-Dickinson FACscan flow cytometer. At
least 10,000 cells were analyzed per sample and graphed using FlowJo soft-
ware (Tree Star Inc.).
Array design and implementation. Quantitative real-time PCR (QPCR) prim-
ers were designed using Primer 3 software (http://frodo.wi.mit.edu/cgi-bin
/primer3/primer3—www.cgi [57]) according to our standard parameters (47).
Where possible, primer sets were chosen to span an intron so as to avoid
background signal from any residual genomic DNA (Table 2). Real-time QPCR
analysis was conducted as previously published (21, 22). The fold induction was
determined for each time point using the following calculation: fold change 
1.8(dCt1  dCt2), where dCt1 and dCt2 are the cycle thresholds normalized to that
of GAPDH at times 1 and 2, respectively). Data were clustered using Array-
Miner to produce a heat map diagram.
Annexin V flow cytometry. BCBL-1, BCP-1, and BC-3 cells were seeded in
duplicate at a density of 2  105 cells/ml in a total of 40 ml. The cultures were
immediately treated with either 5 M Nutlin-3 (racemic) or vehicle (DMSO)
alone. Forty-eight hours later, the cells were counted, spun down, and washed
three times in ice-cold phosphate-buffered saline. Each pellet was resuspended in
Annexin V binding buffer (0.01 M HEPES, pH 7.4, 14 mM NaCl, 2.5 mM CaCl2)
TABLE 1. Analysis of PEL lines
Cell line Reference p53 status DOX IC50(ng/ml) Tumor take (%)
BC-3 2 WT/WT e 7.48 3/3 (100)
VG-1 7 WT/WT 14.9 7/10 (70)
BCLM 29 WT/WT 5.56 4/5 (80)
JSC-1 10 WT/WT 18.0 1/5 (20)
BC-1 12 WT/WT a 4.52 10/10 (100)
BCBL-1 42 WT/M246Ib 31.2 6/7 (86)c
BCP-1 5 S262/S262 Ins 	75.0 6/6 (100)d
a Previously reported by Chadburn et al. (14).
b Previously reported by Katano et al. (38).
c Previously reported by Staudt et al. (65).
d Previously reported by Boshoff et al. (5).
e WT, wild type.
TABLE 2. Primers for real-time QPCR p53 target gene analysis
Target Sense primer (5 to 3) Antisense primer (5 to 3) Size (bp)
p53 AGGCCTTGGAACTCAAGGAT TGAGTCAGGCCCTTCTGTCT 140
p21 GGAAGACCATGTGGACCTGT GGCGTTTGGAGTGGTAGAAA 146
PUMA GACGACCTCAACGCACAGTA CTGGGTAAGGGCAGGAGTC 113
Bcl-2 ATGTGTGTGGAGAGCGTCAA ACAGTTCCACAAAGGCATCC 136
Bax GGGGACGAACTGGACAGTAA CAGTTGAAGTTGCCGTCAGA 122
Bad CGGAGGATGAGTGACGAGT CCACCAGGACTGGAAGACTC 123
APO-1 ATAAGCCCTGTCCTCCAGGT TGGAAGAAAAATGGGCTTTG 120
KILLER GATGGTCAAGGTCGGTGATT CCCCACTGTGCTTTGTACCT 79
cdc25c TCCTTAAAGGCGGCTACAGA GGGCAGTAGCTCTGTGGTTC 70
EZH2 TTCATGCAACACCCAACACT CTCCCTCCAAATGCTGGTAA 96
p53R2 GCCAGGACTCACTTTTTCCA TCAGGCAAGCAAAGTCACAG 71
PIG3 ACGCTGAAATTCACCAAAGG AACCCATCGACCATCAAGAG 107
Gadd45 GGAGGAAGTGCTCAGCAAAG ATCTCTGTCGTCGTCCTCGT 135
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to reach a final concentration of 1  107 cells/ml. Five 100-l aliquots were
generated from each condition, and four were incubated with 5 l of fluorescein
isothiocyanate-conjugated Annexin V antibody (Caltag Laboratories, Burlin-
game, CA) for 15 min at room temperature. The remaining sample was used as
a control. Flow cytometry was performed on 
10,000 cells per sample using a
FacScan instrument and analyzed using FloJo software.
RESULTS
p53 (aa 126 to 331) is wild type in PEL based on sequence
analysis. As p53 is rarely mutated in KS, we hypothesized that
other KSHV-associated tumor types would retain wild-type
p53 status. To test this hypothesis, we examined the genotypes
of seven culture-adapted PEL cell lines. This extensive panel of
cultures is representative of all cells widely utilized in experi-
mental research today (Table 1). All seven lines were KSHV
positive. Two cell lines (BC-1 and JSC-1) were coinfected with
Epstein-Barr virus (EBV) (10, 13). To determine the mutation
status of p53, we employed high-fidelity PCR on PEL-derived
cDNA with primers that cover the previously identified hot
spot region (aa 126 to 331). The corresponding PCR products
were cloned into pBluescript, and at least eight clones were
sequenced per cell line. BCBL-1 cells were determined to be
heterozygous for the M246I mutation as previously reported
(38). BCP-1 cells contained a homozygous insertion at codon
262. All other cell lines contained wild-type p53 sequence.
These data demonstrate that p53 mutations were present in
30% (two of seven) of PEL, all of which grow permanently in
culture and form tumors in nude mice (Table 1 reference 65).
PEL growth is effectively limited by doxorubicin. The cur-
rent standard of care for PEL treatment includes chemother-
apeutics such as anthracyclines (e.g., doxorubicin, daunorubi-
cin, and mitoxantrone). These agents function through DNA
intercalation and oxidative radical formation to induce the
p53-dependent DNA damage pathway (reviewed in reference
28). Since p53 was wild type by sequence in PEL, we assessed
the ability of doxorubicin (Dox) to limit cellular viability. Each
cell line was seeded at equal density in 12-well dishes, and Dox
and/or vehicle (water) was added to the culture at the indicated
dosages. At designated times thereafter, a sample was removed
from each culture and the cellular viability was assessed using
an MTT assay. All treatments were performed in triplicate
wells, and results of the MTT assays directly paralleled those
obtained by trypan blue exclusion counts (data not shown).
The dosages of doxorubicin utilized (0.001 to 0.075 g/ml)
were clinically relevant, as patient serum concentrations of the
drug have been reported to be as high as 11 g/ml following
administration at 60 to 70 mg/m2 (6). As seen in Fig. 1, PEL
lines harboring the wild-type p53 allele (BC-3, VG-1, BCLM,
BC-1, and JSC-1) were susceptible to Dox (complete response
at 0.01 to 0.025 g/ml). This phenotype was independent of
EBV status, as both the JSC-1 and BC-1 cell lines also re-
sponded to Dox treatment. A higher tolerance for Dox was
observed in an allele-specific, dose-dependent manner in both
BCP-1 and BCBL-1 cells. Significantly, BCP-1 proliferation
continued in the presence of 0.075 g/ml Dox. Utilizing data
from day 4, wherein the optimal growth differential was ob-
FIG. 1. PEL lines are sensitive to doxorubicin. (A to G) PEL-derived cell lines were seeded in triplicate at 2  105 cells/ml. The indicated
dosage of doxorubicin (in micrograms/milliliter) and/or vehicle (double-distilled H2O) was added to each sample. Twenty-four hours postseeding
and treatment, a sample was removed and cell survival was scored by MTT assay. Similar MTT measurements were performed every 24 h as
indicated. Raw MTT numbers were normalized to the average reading of the untreated sample at day 1. Data shown represent three independent
points, with error bars indicating the standard deviations. WT, wild type.
1914 PETRE ET AL. J. VIROL.
served for all lines, the IC50 was calculated for each cell line.
Doxorubicin susceptibility directly correlated with p53 status
(Table 1). These results demonstrate that PEL lines containing
the wild-type p53 genotype also exhibit a wild-type p53 phe-
notype as measured by the cell response to the DNA-damaging
agent Dox.
p53 mediates DNA damage-induced growth arrest in PEL.
To assess whether Dox treatment resulted in growth arrest, cell
cycle distribution was determined by propidium iodide (PI)
incorporation. PEL lines were seeded at equal density and
treated with an inhibitory concentration of Dox (0.025 g/ml),
and samples were analyzed at 0, 8, 24, or 48 h following treat-
ment. As seen in Fig. 2, all PEL lines treated with Dox dem-
onstrated marked arrest at the G1/S and G2/M checkpoints,
indicative of a p53-mediated DNA damage response. By 48 h,
the G2/M population of cells harboring wild-type p53 had in-
creased dramatically (between 14 and 38%). In contrast, accu-
mulation of BCP-1 and BCBL-1 cells, which contain a mutant
p53 allele, in G2/M was significantly reduced (less than 10%
increase). Analysis of the sub-G1 population by this method
revealed little apoptotic induction in any of the cell lines within
the time period examined. This observation may be explained
by the relatively slow growth rate of the PEL lines in culture
and/or a molecular mechanism that delays apoptosis. To-
gether, these data support the growth analyses performed in
Fig. 1 and demonstrate that DNA damage in p53 wild-type
PEL lines resulted in cell cycle arrest.
The p53 signaling cascade is fully functional in response to
doxorubicin. To further evaluate p53 function in PEL, we
examined the ability of upstream DNA damage sensors such as
ATM to activate and initiate p53 signaling in Dox-treated cells.
Specifically, PEL lines were seeded at equal density, treated
with an inhibitory concentration of Dox (0.025 g/ml), and
sampled at 0, 8, 24, or 48 h following treatment. Cell pellets
were lysed, and equal protein concentrations were run on SDS-
polyacrylamide gels. The resulting gels were transferred to
nitrocellulose and probed as indicated. p53 phosphorylation on
serine 15 is an indicator of upstream DNA damage signaling
(3, 9) and was readily induced as early as 8 h post-Dox treat-
ment (Fig. 3). Interestingly, BCP-1 cells showed constitutive,
elevated levels of phosphoserine 15. However, p21 was not
induced, suggesting that the S262 insertion leads to a defect in
downstream signaling. All cell lines containing wild-type p53
displayed marked induction of the p53 target gene, p21 (cip1/
waf-1) (24). These data are quantified in Fig. 3B. CDK6 served
as a loading control and remained constant across all samples
and all time points. All cells containing at least one wild-type
copy of p53 responded to drug treatment, whereas the BCP-1
cell line (homozygous mutant) showed no elevation of p53
signaling as measured by p21 induction following Dox treat-
FIG. 2. Doxorubicin induces cell cycle arrest in PEL lines. (A to F) PEL lines were seeded at 2  105 cells per ml and treated the following
day with 0.025 g/ml doxorubicin. Cells were harvested 0, 8, 24, and 48 h posttreatment. The cells were fixed, and DNA content was analyzed by
propidium iodide (PI) flow cytometry. Shown are histograms representing the cell cycle profile of 10,000 cells. WT, wild type.
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ment. These data demonstrate that both upstream and down-
stream p53-dependent signaling was functional in p53 wild-
type PEL irrespective of the presence of KSHV.
Functional p53 is required to mediate DNA damage-induced
inhibition of PEL growth. To test the hypothesis that activation
of p53 is necessary to mediate cell cycle arrest in response to
DNA-damaging agents, we conducted Dox treatment in the
presence of the p53 inhibitor pifithrin  (p-fifty three inhibitor
 [PIF]) (43). BC-3 (wild type/wild type) cells were pretreated
overnight with PIF or vehicle. Dox (0.025 g/ml) and/or ve-
hicle was then added, and cell viability was assessed by MTT
assays. Figure 4A shows our results graphed as the average fold
growth increase relative to the untreated sample on day 1.
PIF-treated, Dox-exposed BC-3 cells demonstrated resis-
tance to doxorubicin and proliferated similarly to the un-
treated controls. By contrast vehicle-treated, Dox-exposed
BC-3 cells ceased to proliferate. PIF or vehicle alone had no
effect. These data imply that p53 is required to inhibit cellular
proliferation following Dox treatment of PEL. Figure 4B
shows the relative growth retardation as a percent of vehicle
control (black bars) for a set of four PEL cell lines at 72 h
posttreatment. PIF alone (gray bar) had no or minor toxicity.
Dox (striped bars) reduced cell growth significantly in the
wild-type BC-3 and BC-1 cells, less in the heterozygous p53
BCBL-1 cells, and not at all in the homozygous p53 BCP-1
cells. PIF (open bars) counteracted the effect of Dox in the
wild-type p53 BC-3 and BC-1 cells but not the p53 mutant cells.
In the p53 heterozygous BCBL-1, PIF seemed to augment
Dox, while in the p53 homozygous mutant p53 BCBP-1 cells
PIF had no effect.
Activation of p53 is sufficient to inhibit PEL growth inde-
pendent of DNA damage. To test the hypothesis that activation
FIG. 3. Doxorubicin treatment of PEL lines activates the p53-mediated DNA damage response. (A) PEL lines were seeded at 2  105 cells per
ml in a total of 2 volumes of 40 ml each. The following morning, the cells were treated with 0.025 g/ml doxorubicin and an initial aliquot of 20
ml was immediately obtained (t  0 h). At the indicated time points following drug addition, cells were collected and pellets were frozen. Lysates
from the time course were quantified, and equal amounts of protein were loaded for SDS-polyacrylamide gel electrophoresis analysis. Gels were
transferred and blotted for the indicated protein products. Here, CDK6 is utilized as a loading control, p21 as a marker for p53 transcriptional
activity, and phosphoserine 15 as an indicator of upstream DNA damage signaling. (B) Using densitometry, p21 expression was normalized to
CDK6 (loading control), and the relative induction over levels observed at 0 h was determined for each time point.
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of p53 is sufficient to mediate the cell cycle arrest in PEL, we
used a recently discovered chemical activator of p53, Nutlin-3.
Nutlins are selective compounds which target the Hdm2-p53
interaction to prevent p53 degradation (67, 68). To test the
efficacy of Nutlin-3 in PEL, we conducted cell viability assays.
Specifically, we seeded our panel of cells at equal density and
added racemic Nutlin-3. Next, cell viability was determined
through trypan blue exclusion counts. Nutlin-3 significantly
reduced cell proliferation in the majority of PEL lines harbor-
ing wild-type p53 (VG-1, BCLM, JSC-1, and BC-1) at low
dosage (2.5 M) (Fig. 5). BC-3 cells displayed resistance to
low-dose Nutlin-3 but ceased proliferation readily at a 5 M
dose. Growth inhibition by Nutlin-3 was compromised at low
doses in PEL cells harboring a mutant p53 allele (BCP-1 and
BCBL-1). As expected, DG75 B-cell lymphoma cells which
harbored mutant p53 (17), but neither KSHV nor EBV, were
completely resistant to Nutlin-3. The p53 dependence of Nutlin-
3 was even more striking when we used Annexin V positivity as
a measure for cell death (Fig. 5I). Thus, Nutlin-3 response
follows p53 status in a gene-dose-dependent manner, i.e., the
susceptibility to Nutlin increased by the following relationship:
homozygous mutant p53 (BCP-1 and S262/S262)  heterozy-
gous mutant p53 (BCBL-1 and M246I)  homozygous wild-
type p53 PEL. This validates Nutlin-3 as a p53-dependent
treatment alternative for PEL. Moreover, use of Nutlin-3 in
these studies demonstrates that p53 activation, independent of
DNA damage, is sufficient to cause cell cycle arrest in PEL.
Nutlin efficacy directly correlates with Hdm2 status (50). To
examine whether increased Hdm2 expression levels can ex-
plain the robust response of PEL to Nutlin, we first examined
Hdm2 mRNA levels in PEL using data from Klein et al. (40),
which represents the transcriptional profile of over 60 B-cell
tumors. Hdm2 mRNA levels served as a class prediction
marker for PEL, clearly separating PEL samples from all oth-
ers in the study (Fig. 5J, top panel). In fact, the predictive value
of Hdm2 mRNA for the classification of PEL was as high as
that of a previously validated marker, the vitamin D receptor
(36). To verify Hdm2 protein expression we performed West-
ern blotting analysis. Hdm2 levels were high and relatively
consistent across all PEL lines (Fig. 5K), with the exception of
BCBL-1 cells, which showed lower Hdm2 levels (Fig. 5L, lane
7). In sum, intact p53 signaling as well as elevated levels of
Hdm2 contribute to the marked sensitivity of PEL to Nutlin-3.
Previous reports demonstrate that the induction of p53 tar-
get genes in response to Nutlin-3 treatment is tumor type
dependent (16, 41, 60, 67). To test the hypothesis that the p53
transcriptional response is consistent across multiple PEL tu-
mors, we developed a quantitative real-time QPCR array for
14 experimentally validated p53 target genes (Table 2). PEL
were treated with 5 M Nutlin-3 (an inhibitory concentration
for all cell lines), and cells were harvested 0, 8, 24, and 48 h
thereafter. RNA was isolated, reverse transcribed, and sub-
jected to real-time QPCR. All PEL lines harboring the wild-
type p53 allele showed induction of p53 target genes in re-
sponse to Nutlin-3, which peaked at 8 h (Fig. 5M). By contrast,
target gene induction was limited in the p53 mutant BCP-1
cells. Neither nontemplate control nor reverse transcriptase-
omitting reactions generated PCR products as determined by
gel electrophoresis and melting curve analysis (data not
shown). These findings suggest that the p53 status of the
BCP-1 line (S262/S262) limits p53 transcriptional capabilities.
The observation that BCBL-1 cells robustly induce all p53
target genes is consistent with the previously reported pheno-
type of the M246I mutation (56) and indicates that BCBL-1
cells may have developed apoptotic resistance through addi-
tional mutations. Together, these findings show that p53 sig-
naling is fully functional in PEL, engaging multiple pathways to
mediate the therapeutic effects of Nutlin-3 and DNA-damag-
ing agents.
DISCUSSION
DNA-damaging chemotherapeutic regimens are clinically
efficacious for the KSHV-associated malignancies KS and
PEL. Typically, the tumor response to chemotherapy is depen-
dent upon functional p53. However, an in-depth analysis of
FIG. 4. PEL response to doxorubicin is p53 dependent. (A) BC-3 cells were seeded in triplicate at 2  105 cells per ml in a 12-well dish with
the indicated amount of pifithrin-alpha (PIF) or vehicle (DMSO). Following 24 h of pretreatment, 0.025 g/ml doxorubicin (DOX) or vehicle
(double-distilled H20) was added to the media. MTT assays were then performed every 24 h post-DOX addition as described in the legend to Fig.
1. Cell growth was normalized to the MTT reading of vehicle-treated cells on day 1. Points represent the average reading of three independent
samples with error bars indicating the standard deviations. (B) Relative growth (percent vehicle control) at 72 h of culture for the indicated PEL
cell lines either mock treated (black bars), PIF treated (gray bars), DOX treated (striped bars), or PIF and DOX treated (open bars). WT, wild
type.
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p53 function in PEL has been missing, because multiple pro-
teins of the PEL-associated human tumor virus KSHV were
shown to inhibit p53 in ectopic expression experiments (27, 31,
48, 55, 61, 62), thus asserting the dogma that all DNA tumor
viruses inactivate p53. If this were true, the presence of KSHV
would severely limit the treatment options for PEL and other
KSHV-associated cancers. PEL should not be responsive to
CHOP, which is in contrast to the clinical experience (64). To
test the hypothesis that p53 is fully functional in PEL despite
the presence of viral oncogenes, we assessed p53 status and
function in response to the prototypical DNA-damaging agent
doxorubicin. Analyzing the most extensive panel of PEL lines
published to date, we find that, similar to KS (38), p53 muta-
tions are rarely detected in PEL (Table 1). DNA damage-
induced p53 activation is intact in PEL harboring wild-type
p53, as evidenced by target gene induction and cell cycle arrest
following treatment with clinically relevant doses of doxorubi-
cin (Fig. 1, 2, and 3). These data imply that in PEL the p53
status dictates the response to chemotherapeutics regardless of
KSHV viral latent proteins.
We corroborated our initial observations by modifying p53
signaling using the well-characterized activator Nutlin-3 (Fig.
5) or the p53 inhibitor pifithrin-alpha (Fig. 4). The phenotypic
response to each of these drugs, as well as the p53-dependent
transcriptional response, correlated tightly with p53 status, ad-
ducing that DNA damage-induced p53 signaling is functional.
How, then, can we reconcile these data with reports demon-
strating disruption of p53 signaling by lytic and latent KSHV
viral proteins? KSHV lytic proteins have been shown to inhibit
p53 function through coactivator sequestration (Rta/ORF50)
(18, 31), repression of ATM-mediated DNA damage signaling
(v-IRF) (62), or other unknown mechanisms (K-bZIP) (48).
Neither Rta/ORF50, K-bZIP, nor vIRF-1 is expressed during
latency in PEL (26). These transcripts are only detectable upon
viral reactivation. Herpesvirus reactivation leads to replication
of the viral genomic DNA, which is resolved through recom-
bination into unit-length pieces that are packed into the virion.
This process generates many DNA double-strand ends, and it
is therefore highly plausible that KSHV evolved to inhibit the
p53/ATM response during the lytic phase of the viral life cycle.
The KSHV latency-associated nuclear antigen (LANA) also
binds and inhibits p53 function in reporter assays (27, 71).
FIG. 5. Nutlin-3 efficacy in PEL is Hdm2 and p53 dependent. (A to H) PEL lines were seeded at 2  105 cells/ml in a total of 5 ml. The indicated
dosage of Nutlin-3 (racemic) or vehicle (DMSO) was then added to the cells. Twenty-four, 48, 72, and 96 h post-Nutlin-3 addition, cell viability
was determined using trypan blue exclusion. DG75 cells do not contain KSHV or EBV. (I) BCBL-1, BCP-1, and BC-3 cells were seeded in media
containing 5 M Nutlin or vehicle (DMSO) alone. Forty-eight hours later, samples were analyzed in quadruplicate for Annexin V positivity. Bar
graphs represent the average Annexin V-positive population in each sample. Error bars show the standard deviation. WT, wild type. (J) Tran-
scription profile analysis of Hdm2 transcript levels in PEL. Using Affymetrix data from 101 B-cell tumors and controls previously recorded by Klein
et al. (40), we identified mRNAs that classify PEL away from all other tumors. These markers include the previously identified vitamin D receptor
(K) and Hdm2 (L) and are shown using a bar graph representation of the average of median-centered mRNA levels for each tumor type. Each
group represents 6 examples. (BL, Burkitt’s lymphoma; DLBL, diffuse large B-cell lymphoma; CB, centroblastic; IB, immunoblastic). (M) PEL
lines grown in complete media were harvested, and lysates were quantified. Equal protein quantities were separated by SDS-polyacrylamide gel
electrophoresis, transferred, and immunoblotted for Hdm2, p53, and CDK6 (loading control) expression (top panel). Band intensities were
quantified using ImageQuant software and normalized to CDK6. (N) The relative expression of Hdm2. (O) PEL lines were seeded, treated with
5 M Nutlin-3, and harvested at increasing time points as described in the legend to Fig. 3. Following RNA isolation, cDNA was generated using
random hexamer-primed reverse transcription. cDNA was subjected to quantitative real-time PCR for the indicated targets. Data were collected,
and the relative change in gene expression was determined by calculating the difference between dCt1 and dCt2. Data were analyzed using
ArrayMiner. Red represents gene induction relative to the median of all genes and data points in the array.
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Conversely, p53 can inhibit the LANA promoter (37). Unlike
the lytic proteins, LANA is constitutively expressed in all PEL
cells (19, 23, 66). LANA, like p53, is a relatively “sticky” pro-
tein, binding to many partners in vitro. Due to the multitude of
LANA binding partners (10) and functions (63), it has been
considerably more difficult to establish the specificity and func-
tionality of the p53-LANA complex. LANA binds to the his-
tone core components H2A, H2B, and H1, thereby tethering
the viral episome to host chromatin (4). This interaction results
in the characteristic nuclear speckled pattern observed using
LANA-specific monoclonal antibodies (39, 54). It is conceiv-
able that some p53 would be sequestered into these complexes,
which also contain Ku70, Ku80, and PARP-1. The results pre-
sented here show that the nature of the LANA-p53 complex is
such that enough functional p53 is available to mediate PEL
cell cycle inhibition in response to DNA damage or to Nutlin-3.
In fact, upon Nutlin-3 treatment p53 and LANA occupy dis-
tinct, nonoverlapping nuclear compartments (Fig. S1 in the
supplemental material).
The rarity of p53 mutations observed herein expands upon
an earlier report (46), which similarly did not detect p53
mutations in primary PEL biopsies. The p53 mutations in
two of the cell lines examined (Table 1) may reflect the
origins of the patient samples. BCP-1 cells (p53, S262/S262)
were derived from an HIV-negative, 94-year-old man with
previous history of both KS and colon cancer (5). This
individual was treated for 3 years with prolonged chemo-
therapy before succumbing to the disease, whereupon the
BCP-1 cell line was isolated. Likewise, BCBL-1 (wild type/
M246I) cells were derived from an HIV-positive patient who
underwent prior chemotherapeutic treatment with doxoru-
bicin (42). Unlike other primary effusions, which typically
fail to grow after a period of 14 days upon explantation in
culture, BCBL-1 cells grew rapidly with no discernible lag
phase (B. Herndier and D. Ganem, personal communica-
tion). BCLM and JSC-1 were isolated prior to therapeutic
administration and maintained wild-type p53 function.
Thus, long-term PEL culture is compatible with p53 activity,
and only prolonged treatment with DNA-damaging agents
in vivo appears to select for p53 mutations.
The M246I and S262 mutations identified in these PEL lines
were previously reported in other cancers. The M246I muta-
tion (BCBL-1) was initially identified in the H23 lung cancer
cell line and was reported to maintain DNA binding to con-
sensus p53 binding elements (56). However, transactivation of
nonconsensus elements by p53 M246I was limited, resulting in
decreased apoptotic induction. While the Mdm2 promoter
(consensus element) was effectively induced by M246I, PIG3
(nonconsensus) transactivation was significantly reduced. This
is consistent with the phenotype of BCBL-1 cells, which dem-
onstrated intense induction of p53 target genes following
Nutlin-3 treatment yet failed to undergo significant apoptosis
(Fig. 5). Far less is known about the p53 S262 insertion mutant.
Previously identified in pancreatic cancer (11), a characteriza-
tion of the mutant has yet to be conducted. Our findings
suggest that S262 has little transactivation potential, as few
genes were induced in the Nutlin-3 array studies. Additionally,
BCP-1 cells (S262/S262) demonstrated a low background level
of all p53 transcripts assayed, further implying that this signal-
ing pathway is disrupted (data not shown). Understanding how
individual p53 mutations contribute to therapeutic response
will be essential to providing individualized PEL therapy.
Structural studies of the p53-Mdm2 interaction have re-
vealed evidence that three key residues (Phe, Trp, and Lev) of
p53 bind to a deep cavity on the Mdm2 surface (44). Nutlins
represent the most potent and selective inhibitors of this in-
teraction described to date. Nutlins are cis-imidizoline analogs,
capable of penetrating cellular membranes, and thus can be
administered orally (68). Nutlin-3 was well tolerated in murine
xenograph studies (up to 200 mg/g of body weight twice daily),
wherein the growth of p53-positive tumors was inhibited (67).
Recent studies implicate Nutlin-3 as a novel therapeutic for
B-cell chronic lymphocytic leukemia (B-CLL) and acute my-
eloid leukemia (AML) (16, 41, 60). Interestingly, these previ-
ous studies utilized the purified, active Nutlin-3a enantiomer.
Herein, we studied the effects of the racemic mixture (contain-
ing a 1:1 ratio of active [3a] versus inactive [3b] enantiomer).
By comparison, PELs were more sensitive to Nutlin-3 treat-
ment than B-CLL and AML (Fig. 5; 2.5 to 5.0 M racemic
versus 4.7 and 5 M Nutlin-3a, respectively), perhaps reflect-
ing their phenotypically elevated Hdm2 expression. PELs har-
boring the wild-type p53 allele exhibited significant apoptosis
following Nutlin-3 treatment; however, PEL lines with ho-
mozygous, mutant p53 failed to proliferate only at increased
doses of drug (Fig. 5). BC-3 cells deviated somewhat from the
phenotype of other p53 wild-type cell lines, and further studies
are under way to clarify this phenotype. One possible explana-
tion is that BC-3 cells express a high level of HdmX (unpub-
lished observation). Increased HdmX levels would explain
their partial resistance to Nutlin-3, since Nutlin-3 fails to block
the p53-HdmX interaction (50). Alternatively, Nutlin-3 may
affect other targets than p53 (25, 70). A key finding of this
study is that Hdm2 is overexpressed in PEL. Moreover,
Hdm2 mRNA levels can be utilized to classify PEL away
from diffuse large B-cell lymphoma and other B-cell-lym-
phoproliferative diseases (Fig. 5). The underlying mecha-
nism for this phenotype is currently under investigation.
Regardless, these data explain the dramatic susceptibility of
this tumor type to Nutlin-3.
The use of a novel targeted p53 real-time QPCR array al-
lowed us to molecularly characterize PEL response to Nutlin-3.
Activation of the p53 transcriptome following Nutlin-3 addi-
tion differs between PEL and other hematological malignan-
cies. In B-CLL, Nutlin-3a activates Mdm2, p21, and PUMA
expression but not BAX (16). In AML, Nutlin-3a activates
Mdm2, p21, and NOXA but not PUMA or BAX (41). Here we
find that in PEL, Nutlin-3 rapidly (8 h) activates multiple p53
targets, including p21, NOXA, PUMA, and BAX (Fig. 5).
Independent of the specific transcriptional targets activated,
the cellular outcome, namely growth inhibition and apoptosis,
is the same for PEL, B-CLL, and AML. PEL is a rapidly
progressing disease, wherein the immunocompromised status
of the patient often influences the physician’s ability to admin-
ister therapy. Our findings suggest that determination of p53
and Hdm2 status is critical to the assessment of potential
therapeutic regimens. KSHV oncogenes did not influence the
ability of PEL to respond to DNA-damaging agents. However,
they may modulate p53 function at steady-state growth or
during KSHV lytic replication. Nutlins and other p53-activat-
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ing compounds may prove highly efficacious for the treatment
of PEL patients.
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